Jazz Pharmaceuticals Plc Stock Net Income
| JAZZ Stock | USD 125.05 0.42 0.34% |
Jazz Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.
Jazz |
Jazz Pharmaceuticals PLC Company Net Income Analysis
Jazz Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Jazz Pharmaceuticals Net Income | 414.83 M |
Most of Jazz Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Jazz Pharmaceuticals PLC reported net income of 414.83 M. This is 21.55% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 27.35% higher than that of the company.
Jazz Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.Jazz Pharmaceuticals is currently under evaluation in net income category among its peers.
Jazz Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0462 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 11.1 B | ||||
| Shares Outstanding | 60.45 M | ||||
| Shares Owned By Insiders | 2.93 % | ||||
| Shares Owned By Institutions | 98.43 % | ||||
| Number Of Shares Shorted | 4.26 M | ||||
| Price To Earning | 35.18 X | ||||
| Price To Book | 1.80 X | ||||
| Price To Sales | 1.85 X | ||||
| Revenue | 3.83 B | ||||
| Gross Profit | 3.7 B | ||||
| EBITDA | 1.23 B | ||||
| Net Income | 414.83 M | ||||
| Cash And Equivalents | 899.36 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 5.79 B | ||||
| Debt To Equity | 2.12 % | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 69.01 X | ||||
| Cash Flow From Operations | 1.09 B | ||||
| Short Ratio | 7.04 X | ||||
| Earnings Per Share | 7.06 X | ||||
| Price To Earnings To Growth | 0.85 X | ||||
| Target Price | 180.95 | ||||
| Number Of Employees | 2.8 K | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 7.37 B | ||||
| Total Asset | 11.39 B | ||||
| Retained Earnings | 878.66 M | ||||
| Working Capital | 1.9 B | ||||
| Current Asset | 1.26 B | ||||
| Current Liabilities | 226.64 M | ||||
| Net Asset | 11.39 B |
About Jazz Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.